SAB Biotherapeutics opened lower at $3.10, compared with its previous close of $3.11. In the last trading session, the stock traded between $3.01 and $3.22. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in SAB Biotherapeutics is now worth
$ 3.29
Resulting in a loss of
$ 96.71 (96.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-0.84%)
Day High
$3.22
Day Low
$3.01
Day Open
$3.10
Prev Close
$3.11
Volume
20,38,720
1W Return
-2.68%
1M Return
9.17%
3M Return
-18.09%
6M Return
-17.10%
1Y Return
-5.69%
Fundamentals
Market Cap ($ Mn)
278
PE Ratio
-
PB Ratio
1.47
PEG Ratio
-
ROE
17.65%
ROCE
14.42%
EPS (TTM)
$-0.24
Investment Returns
1 Week
-2.68%
1 Month
9.17%
3 Months
-18.09%
6 Months
-17.10%
9 Months
-26.22%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
5Nov
SAB Biotherapeutics holds $205M cash, gets FDA Fast Track for SAB142
Cash position stands at $205 million, funding operations through 2028. FDA grants Fast Track designation to SAB142 for stage 3 type 1 diabetes. Net loss of $22.3 million in Q3 2026 versus net income of $45.4 million in Q3 2025. R&D expenses rise to $18.1 million due to Safeguard study advancement.
7 days ago
7Jul
Breakthrough T1D awards grant for SAB-142 study in new-onset T1D
Breakthrough T1D awarded a grant to the University of Florida to support the PRISE-hATG study evaluating SAB-142 in Stage 3 T1D patients. The study aims to preserve endogenous C-peptide and modulate immune responses in individuals 100 days to 2 years from diagnosis. SAB Biotherapeutics will co-fund the study, which complements the ongoing Phase 2b SAFEGUARD trial.
4mo ago
25Jun
Barclays initiates coverage on SAB Biotherapeutics with Overweight rating
Barclays analyst Eliana Merle initiated coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13, signaling a positive outlook.
4mo ago
17Jun
Chardan Capital raises SAB Biotherapeutics target to $16
Chardan Capital analyst Keay Nakae maintained a Buy rating on SAB Biotherapeutics and raised the price target to $16 from $14.
4mo ago
15Jun
Leerink Partners raises SAB Biotherapeutics target to $12
Leerink Partners analyst Thomas Smith maintained an Outperform rating on SAB Biotherapeutics and raised the price target to $12 from $7.
5mo ago
15Jun
HC Wainwright reiterates Buy on SAB Biotherapeutics
HC Wainwright & Co. analyst Emily Bodnar reaffirms a Buy rating for SAB Biotherapeutics (NASDAQ: SABS) with a maintained price target of $10, highlighting confidence in the company's prospects.
